Michael Klichinsky is the co-founder and chief scientific officer of Carisma Therapeutics, which is developing macrophage-based cell therapies for cancer.
November 7, 2023 10:23 AM ESTUpdated 11:53 AM
Cell/Gene Tx
In Focus

mR­NA’s next trick? Re­pro­gram­ming off-the-shelf cell ther­a­pies for can­cer and au­toim­mune dis­eases

Ryan Cross

Senior Science Correspondent

Lei Lei Wu

News Reporter

A hand­ful of biotechs, in­clud­ing Mod­er­na, are bet­ting that sim­ple in­fu­sions with mR­NA could su­per­charge im­mune cells to fight can­cer and oth­er dis­eases in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: No­vo Nordisk CEO to step down amid stock de­cline, time­line for suc­ces­sor un­known

Deputy FDA chief mulls shak­ing up PDU­FA reau­tho­riza­tion struc­ture

Low­er at­ten­dance at cell and gene ther­a­py con­fer­ence mir­rors chal­lenged in­dus­try

FDA pos­es ef­fi­ca­cy, safe­ty ques­tions over four can­cer drugs ahead of two-day ad­comm

No­vo Nordisk’s glob­al obe­si­ty leader is mov­ing on; Flag­ship biotech gets CEO from Schol­ar Rock

'Go ahead and do it': Top RFK Jr. deputy dares drug­mak­ers that might pull man­u­fac­tur­ing over new price pres­sure

A service from the Financial Times